Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer

Mohammad Hoque, Qinghua Feng, Papa Toure, Amadou Dem, Cathy W. Critchlow, Stephen E. Hawes, Troy Wood, Carmen Jeronimo, Eli Rosenbaum, Joshua Stern, Mujun Yu, Barry Trink, Nancy B. Kiviat, David Sidransky

Research output: Contribution to journalArticle

Abstract

Purpose: Novel approaches to breast cancer screening are necessary, especially in the developing world where mammography is not feasible. In this study, we explored the hypothesis that blood-based biomarkers have potential for biomarkers for breast cancer. Patients and Methods: We first determined the frequency of aberrant methylation of four candidate genes (APC, GSTP1, Rassf1A, and RARβ2) in primary breast cancer tissues from West African women with predominantly advanced cancers. We used a high-throughput DNA methylation assay (quantitative methylation-specific polymerase chain reaction) to examine plasma from 93 women with breast cancer and 76 controls for the presence of four methylated genes. Samples were randomly divided evenly into training and validation data sets. Cutoff values for gene positivity of the plasma-based assay and the gene panel were determined by receiver operating characteristic curves in the training data set and subsequently evaluated as a screening tool in the validation data set. Results: Methylation of at least one gene resulted in a sensitivity of 62% and a specificity of 87%. Moreover, the assay successfully detected 33% (eight of 24) of early-stage tumors. Conclusion: These data suggest that epigenetic markers in plasma may be of interest for detection of breast cancer. Identification of additional breast cancer specific methylated genes with higher prevalence in early stage cancers would improve this approach.

Original languageEnglish (US)
Pages (from-to)4262-4269
Number of pages8
JournalJournal of Clinical Oncology
Volume24
Issue number26
DOIs
StatePublished - Sep 10 2006

Fingerprint

Methylation
Breast Neoplasms
DNA
Genes
Biomarkers
APC Genes
Neoplasms
DNA Methylation
Mammography
Early Detection of Cancer
Epigenomics
ROC Curve
Polymerase Chain Reaction
Datasets

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. / Hoque, Mohammad; Feng, Qinghua; Toure, Papa; Dem, Amadou; Critchlow, Cathy W.; Hawes, Stephen E.; Wood, Troy; Jeronimo, Carmen; Rosenbaum, Eli; Stern, Joshua; Yu, Mujun; Trink, Barry; Kiviat, Nancy B.; Sidransky, David.

In: Journal of Clinical Oncology, Vol. 24, No. 26, 10.09.2006, p. 4262-4269.

Research output: Contribution to journalArticle

Hoque, M, Feng, Q, Toure, P, Dem, A, Critchlow, CW, Hawes, SE, Wood, T, Jeronimo, C, Rosenbaum, E, Stern, J, Yu, M, Trink, B, Kiviat, NB & Sidransky, D 2006, 'Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer', Journal of Clinical Oncology, vol. 24, no. 26, pp. 4262-4269. https://doi.org/10.1200/JCO.2005.01.3516
Hoque, Mohammad ; Feng, Qinghua ; Toure, Papa ; Dem, Amadou ; Critchlow, Cathy W. ; Hawes, Stephen E. ; Wood, Troy ; Jeronimo, Carmen ; Rosenbaum, Eli ; Stern, Joshua ; Yu, Mujun ; Trink, Barry ; Kiviat, Nancy B. ; Sidransky, David. / Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 26. pp. 4262-4269.
@article{0b32ef92ce36477fa39b7d29703c4552,
title = "Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer",
abstract = "Purpose: Novel approaches to breast cancer screening are necessary, especially in the developing world where mammography is not feasible. In this study, we explored the hypothesis that blood-based biomarkers have potential for biomarkers for breast cancer. Patients and Methods: We first determined the frequency of aberrant methylation of four candidate genes (APC, GSTP1, Rassf1A, and RARβ2) in primary breast cancer tissues from West African women with predominantly advanced cancers. We used a high-throughput DNA methylation assay (quantitative methylation-specific polymerase chain reaction) to examine plasma from 93 women with breast cancer and 76 controls for the presence of four methylated genes. Samples were randomly divided evenly into training and validation data sets. Cutoff values for gene positivity of the plasma-based assay and the gene panel were determined by receiver operating characteristic curves in the training data set and subsequently evaluated as a screening tool in the validation data set. Results: Methylation of at least one gene resulted in a sensitivity of 62{\%} and a specificity of 87{\%}. Moreover, the assay successfully detected 33{\%} (eight of 24) of early-stage tumors. Conclusion: These data suggest that epigenetic markers in plasma may be of interest for detection of breast cancer. Identification of additional breast cancer specific methylated genes with higher prevalence in early stage cancers would improve this approach.",
author = "Mohammad Hoque and Qinghua Feng and Papa Toure and Amadou Dem and Critchlow, {Cathy W.} and Hawes, {Stephen E.} and Troy Wood and Carmen Jeronimo and Eli Rosenbaum and Joshua Stern and Mujun Yu and Barry Trink and Kiviat, {Nancy B.} and David Sidransky",
year = "2006",
month = "9",
day = "10",
doi = "10.1200/JCO.2005.01.3516",
language = "English (US)",
volume = "24",
pages = "4262--4269",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "26",

}

TY - JOUR

T1 - Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer

AU - Hoque, Mohammad

AU - Feng, Qinghua

AU - Toure, Papa

AU - Dem, Amadou

AU - Critchlow, Cathy W.

AU - Hawes, Stephen E.

AU - Wood, Troy

AU - Jeronimo, Carmen

AU - Rosenbaum, Eli

AU - Stern, Joshua

AU - Yu, Mujun

AU - Trink, Barry

AU - Kiviat, Nancy B.

AU - Sidransky, David

PY - 2006/9/10

Y1 - 2006/9/10

N2 - Purpose: Novel approaches to breast cancer screening are necessary, especially in the developing world where mammography is not feasible. In this study, we explored the hypothesis that blood-based biomarkers have potential for biomarkers for breast cancer. Patients and Methods: We first determined the frequency of aberrant methylation of four candidate genes (APC, GSTP1, Rassf1A, and RARβ2) in primary breast cancer tissues from West African women with predominantly advanced cancers. We used a high-throughput DNA methylation assay (quantitative methylation-specific polymerase chain reaction) to examine plasma from 93 women with breast cancer and 76 controls for the presence of four methylated genes. Samples were randomly divided evenly into training and validation data sets. Cutoff values for gene positivity of the plasma-based assay and the gene panel were determined by receiver operating characteristic curves in the training data set and subsequently evaluated as a screening tool in the validation data set. Results: Methylation of at least one gene resulted in a sensitivity of 62% and a specificity of 87%. Moreover, the assay successfully detected 33% (eight of 24) of early-stage tumors. Conclusion: These data suggest that epigenetic markers in plasma may be of interest for detection of breast cancer. Identification of additional breast cancer specific methylated genes with higher prevalence in early stage cancers would improve this approach.

AB - Purpose: Novel approaches to breast cancer screening are necessary, especially in the developing world where mammography is not feasible. In this study, we explored the hypothesis that blood-based biomarkers have potential for biomarkers for breast cancer. Patients and Methods: We first determined the frequency of aberrant methylation of four candidate genes (APC, GSTP1, Rassf1A, and RARβ2) in primary breast cancer tissues from West African women with predominantly advanced cancers. We used a high-throughput DNA methylation assay (quantitative methylation-specific polymerase chain reaction) to examine plasma from 93 women with breast cancer and 76 controls for the presence of four methylated genes. Samples were randomly divided evenly into training and validation data sets. Cutoff values for gene positivity of the plasma-based assay and the gene panel were determined by receiver operating characteristic curves in the training data set and subsequently evaluated as a screening tool in the validation data set. Results: Methylation of at least one gene resulted in a sensitivity of 62% and a specificity of 87%. Moreover, the assay successfully detected 33% (eight of 24) of early-stage tumors. Conclusion: These data suggest that epigenetic markers in plasma may be of interest for detection of breast cancer. Identification of additional breast cancer specific methylated genes with higher prevalence in early stage cancers would improve this approach.

UR - http://www.scopus.com/inward/record.url?scp=33749024160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749024160&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.01.3516

DO - 10.1200/JCO.2005.01.3516

M3 - Article

C2 - 16908936

AN - SCOPUS:33749024160

VL - 24

SP - 4262

EP - 4269

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 26

ER -